Table 1.
Demographic and clinical characteristics of the patients with multisystem inflammatory syndrome in children (MIS‐C)
| Characteristic | All patients (n = 101) | Laboratory confirmation of SARS‐CoV‐2 infection (n = 83) | Epidemiologic link to person with COVID‐19 (n = 18) | |
|---|---|---|---|---|
| RT‐PCR positive (n = 25) | Antibody test positive. RT‐PCR negative (n = 58) | |||
| Age, median (IQR), year | 7.08 (4.6–9.3) | 6.08 (2.1–12.3) | 7.25 (5.5–9.87) | 4.91 (1.1–8.41) |
| Sex, no. (%) | ||||
| Boy | 51 (50.5) | 10 (40) | 31 (53.4) | 10 (55.6) |
| Girl | 50 (49.5) | 15 (60) | 27 (46.6) | 8 (44.4) |
| Race/ethnicity (%) | ||||
| Turkish | 97 (96) | 25 (100) | 55 (94.8) | 17 (94.4) |
| Others | 4 (4) | 0 | 3 (5.2) | 1 (5.6) |
| Age group, no (%) | ||||
| 0–5 y | 29 (28.7) | 10 (40) | 9 (15.5) | 10 (55.5) |
| 5–12 y | 56 (55.4) | 8 (32) | 42 (72.4) | 6 (33.4) |
| >12 y | 16 (15.9) | 7 (28) | 7 (12.1) | 2 (11.1) |
| BMI percentile median/patient no. (IQR) | 39.7/97 (14.5–83) | 44.4/25 (18.5–83.8) | 41.9/54 (11.52–83.2) | 31.5/18 (14.7–84.7) |
| Overweight, patient no./total no. (%) | 13/97 (13.4) | 3/25 (12) | 7/54 (12.9) | 3/18 (16.6) |
| Obese. patient no./total no. (%) | 9/97 (9.2) | 3/25 (12) | 5/54 (9.2) | 1/18 (5.5) |
| Clinical features at presentation | ||||
| Fever, n (%) | 101 (100) | 25 (100) | 58 (100) | 18 (100) |
| Degree of fever (°C), median (IQR) | 39 (38.6–39.5) | 39 (38.5–39) | 39 (38.7–39.5) | 39 (38.9–39.6) |
| Duration of fever (day), median (IQR) | 7 (5–7.5) | 7 (6–7.5) | 6.5 (5–8) | 6.5 (5–7) |
| Fatigue, n (%) | 90 (89.1) | 19 (76) | 55 (94.8) | 16 (88.8) |
| Gastrointestinal symptoms, n (%) | 81 (80.2) | 19 (76) | 48 (82.8) | 14 (77.8) |
| Abdominal pain, patient no./total no. (%) | 68/85 (80) | 15/17 (88.2) | 41/55 (74.5) | 12/13 (92.3) |
| Vomiting, n (%) | 55 (54.5) | 14 (56) | 30 (51.7) | 11 (61.1) |
| Nausea, patient no./total no. (%) | 57/95 (60) | 13/19 (68.4) | 33/58 (56.8) | 11/18 (61.1) |
| Diarrhoea, n (%) | 43 (42.5) | 9 (36) | 26 (44.8) | 8 (44.4) |
| Conjunctival injection, n (%) | 65 (64.4) | 10 (40) | 45 (77.6) | 10 (55.6) |
| Rash, n (%) | 65 (64.4) | 14 (56) | 37 (63.8) | 14 (77.8) |
| Maculopapular | 33 (32.6) | 6 (24) | 18 (31) | 9 (50) |
| Macule | 29 (28.7) | 7 (28) | 17 (29.3) | 5 (27.7) |
| Petechiae/ecchymosis | 3 (2.9) | 1 (4) | 2 (3.4) | 0 |
| Muscle ache, patient no./total no. (%) | 60/85 (70.5) | 12/18 (66.6) | 37/56 (66) | 11/11 (100) |
| Mucous membrane changes, n (%) | 59 (58.4) | 8 (32) | 37 (63.8) | 14 (77.8) |
| Peripheral cutaneous inflammation signs, n (%) | 46 (45.5) | 9 (36) | 27 (46.6) | 10 (55.6) |
| Any respiratory symptoms, n (%) | 44 (38.6) | 9 (36) | 28 (48.3) | 7 (38.9) |
| Arthralgia, patient no./total no. (%) | 40/85 (47) | 10/17 (58.8) | 21/55 (38.1) | 9/13 (69.2) |
| Shock, n (%) | 39 (38.6) | 7 (28) | 24 (41.3) | 8 (44.4) |
| Headache, patient no./total no. (%) | 36/79 (45.5) | 9/17 (52.9) | 23/52 (44.2) | 4/10 (40) |
| Sore throat, patient no./total no. (%) | 24/82 (29.2) | 6/18 (33.3) | 14/54 (25.9) | 4/10 (40) |
| Dry cough, n (%) | 23 (22.8) | 5 (20) | 16 (27.6) | 2 (11.1) |
| Lethargy, n (%) | 23 (22.8) | 6 (24) | 10 (17.2) | 7 (38.8) |
| Desquamation, n (%) | 20 (19.8) | 4 (16) | 10 (17.2) | 6 (33.3) |
| Joint swelling, n (%) | 11 (10.9) | 3 (12) | 6 (10.3) | 2 (11.1) |
| Ileus, n (%) | 9 (8.9) | 2 (8) | 3 (5.2) | 4 (22.2) |
| Odynophagia, n (%) | 8/82 (9.7) | 2/17 (11.7) | 3/55 (5.4) | 3/10 (30) |
| Lymphadenopathy, n (%) | 7 (6.9) | 1 (4) | 4 (6.8) | 2 (11.1) |
| Taste loss, patient no./total no. (%) | 5/83 (6) | 0/18 | 2/55 (3.6) | 3/10 (30) |
| Runny nose, n (%) | 4 (3.9) | 1 (4) | 2 (3.4) | 1 (5.6) |
| Loss of smell, patient no./total no. (%) | 3/83 (3.6) | 1/18 (5.5) | 1/55 (1.81) | 1/10 (10) |
BMI, body mass index; IQR, interquartile range; RT‐PCR, reverse‐transcriptase polymerase chain reaction; SARS‐CoV‐2, severe acute respiratory syndrome virus 2.